Table 1.
Distribution of Biomarker Values Studied in the TARGET Trial Cohort by Treatment Group
| Cytokine/inflammation, units, median (IQR) | Total cohort | TNFi | Triple therapy | P value |
|---|---|---|---|---|
| n=109 | n=55 | n=54 | ||
| IL‐6, pg/mL | 11 (5–23) | 11 (5–22) | 11 (6–22) | 0.2 |
| sTNFR1, pg/mL | 1327 (1097–1712) | 1316 (1104–1718) | 1392 (1068–1699) | 0.7 |
| SAA, ng/mL | 15 478 (7674–42 875) | 14 994 (6555–51 327) | 16 371 (8560–30 635) | 0.4 |
| hsCRP, μg/mL | 4 (2–9) | 4 (1–8) | 4 (2–9) | 0.8 |
| CD‐40 ligand, ng/mL | 0.10 (0.06–0.23) | 0.11 (0.07–0.27) | 0.09 (0.05–0.17) | 0.2 |
| Adipokines | ||||
| Adiponectin, μg/mL | 7.1 (4.5–9.8) | 7.1 (4.5–11.2) | 7.2 (4.8–9.2) | 0.6 |
| Leptin, ng/mL | 22 (11–37) | 21 (12–36) | 26 (11–40) | 0.8 |
| Resistin, ng/mL | 2.84 (2.40–3.73) | 2.81 (2.44–3.67) | 2.86 (2.40–3.74) | 0.5 |
| Atherothrombosis | ||||
| Antithrombin III, μg/mL | 453 (389–522) | 453 (396–532) | 444 (381–504) | 0.6 |
| PAI‐1, ng/mL | 75 (45–117) | 70 (44–133) | 76 (48–11 209) | 0.4 |
| Lipids parameters | ||||
| Apolipoprotein C3, μg/mL | 301 (244–407) | 293 (240–398) | 328 (250–412) | 0.3 |
| Apolipoprotein A1, mg/mL | 2.10 (1.80–2.70) | 2.02 (1.85–2.60) | 2.25 (1.80–2.80) | 0.3 |
| Apolipoprotein A2, ng/mL | 329 (257–393) | 318 (244–388) | 343 (288–397) | 0.3 |
| Apolipoprotein B, μg/mL | 909 (674–1090) | 974 (714–1155) | 812 (660–1025) | 0.2 |
| Apolipoprotein C1, μg/mL | 348 (256–402) | 339 (238–433) | 354 (274–393) | 0.9 |
| Lp(a), μg/mL | 105 (48–247) | 105 (47–328) | 104 (50–236) | 0.3 |
| LDL, mg/dL | 99 (82–122) | 101 (81–126) | 98 (86–119) | 0.8 |
| Other analytes | ||||
| hsTnT, ng/L* | 60 (55%) | 32 (58%) | 28 (52%) | 0.5 |
| NT‐proBNP, pg/mL | 356 (192–737) | 350 (149–738) | 368 (258–710) | 0.9 |
| VCAM‐1, ng/mL | 608 (508–737) | 625 (507–783) | 607 (525–682) | 0.2 |
| VEGF‐A, pg/mL | 153 (99–207) | 162 (104–208) | 134 (89–200) | 0.2 |
| MMP‐1, ng/mL | 7636 (4652–11 270) | 7872 (5378–12 292) | 7545 (3955–10 558) | 0.4 |
| MMP‐3, ng/mL | 6 (4–14) | 7 (4–15) | 6 (4–13) | 0.3 |
| YKL‐40, ng/mL | 30 (21–61) | 31 (23–63) | 30 (21–61) | 0.6 |
| Cystatin‐C, ng/mL | 1140 (982–1290) | 1120 (990–1275) | 1160 (968–1380) | 0.5 |
| Osteopontin, ng/mL | 33 (25–44) | 33 (24–44) | 34 (25–44) | 0.9 |
| Osteoprotegrin, pM | 7.80 (6.50–9.70) | 7.90 (6.55–9.15) | 7.75 (6.43–10.00) | 0.3 |
CT indicates computed tomography; hsCRP, high‐sensitivity C‐reactive protein; FDG, fluorodeoxyglucose; hsTnT, high sensitivity troponin T; IL, interleukin; IQR, interquartile range; LDL, low‐density lipoprotein; Lp(a), lipoprotein(a); MMP‐1, matrix metalloproteinase 1; MMP‐3, matrix metalloproteinase 3; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; PAI‐1, plasminogen activator inhibitor‐1; PET, positron emission tomography; RA, rheumatoid arthritis; SAA, serum amyloid A; sTNFR1, soluble tumor necrosis factor receptor 1; TARGET, Treatments Against RA and Effect on FDG PET/CT; TNFi, tumor necrosis factor inhibitor; VCAM‐1, vascular cell adhesion molecule 1; and VEGF‐A, vascular endothelial growth factor A.
hsTnT data represent the n (%) with detectable levels. Other subjects were below detectable range. P values were calculated from the Welch 2‐sample t test.